Apatinib emerged as the conspicuous VEGFR2-TKI and anti-angiogenic agent for patients with PLC and could inhibit proliferation and induce apoptosis in hepatoma carcinoma cells (Zhang et al., 2018; Wen, 2019), in addition to limiting the angiogenesis of tumor tissues (He et al., 2020). Here, HSPG2 is linked to neoplasm.